<h2 dir="ltr">Metastatic Colorectal Cancer</h2>
Metastatic Colorectal Cancer (mCRC) is an advanced stage of colorectal cancer where the disease has spread beyond the colon or rectum to other parts of the body, most commonly the liver and lungs. It often develops from untreated or recurrent primary colorectal tumors. Treatment typically involves chemotherapy, targeted therapy, and immunotherapy, depending on genetic markers like KRAS, NRAS, and BRAF. Prognosis varies, but early detection and personalized treatment can improve outcomes.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Incident cases of CRC
</li>
<li dir="ltr" aria-level="1">
Gender-specific cases of CRC
</li>
<li dir="ltr" aria-level="1">
Age-specific cases of CRC
</li>
<li dir="ltr" aria-level="1">
Tumor location-specific cases of CRC
</li>
<li dir="ltr" aria-level="1">
Stage-specific cases of CRC
</li>
<li dir="ltr" aria-level="1">
Total Incident cases of mCRC
</li>
<li dir="ltr" aria-level="1">
Mutation Type-specific cases of mCRC
</li>
<li dir="ltr" aria-level="1">
Total treated cases of mCRC by line of therapy
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-epidemiology-forecast">Metastatic Colorectal Cancer Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, mCRC incident cases in the 7MM were ~295K, with numbers expected to rise by 2034.
</li>
<li dir="ltr" aria-level="1">
In 2024, the U.S. reported ~79K incident mCRC cases.
</li>
<li dir="ltr" aria-level="1">
CRC cases by gender were ~85K in males and ~67K in females.
</li>
<li dir="ltr" aria-level="1">
The highest incidence was in the 65&ndash;84 age group (~68K cases), followed by 45&ndash;64 years (~57K cases).
</li>
<li dir="ltr" aria-level="1">
Most CRC cases occurred in the right colon, followed by the left colon, transverse colon, and rectum.
</li>
<li dir="ltr" aria-level="1">
Germany led mCRC incidence in the EU4 and UK with over 33K cases in 2024.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market">Metastatic Colorectal Cancer Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the mCRC market in the 7MM exceeded USD 13 billion and is projected to grow by 2034.
</li>
<li dir="ltr" aria-level="1">
The U.S. held the largest share, accounting for ~45% of the total market.
</li>
</ul>
<h3 dir="ltr">Metastatic Colorectal Cancer Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The growing adoption of biomarker testing (e.g., KRAS, NRAS, BRAF, MSI-H/dMMR, HER2) is enabling more personalized treatment strategies in metastatic colorectal cancer. Targeted therapies like anti-EGFR agents (cetuximab, panitumumab), BRAF inhibitors, and immune checkpoint inhibitors for MSI-H tumors are improving outcomes in biomarker-defined subgroups, driving market expansion through precision oncology.
</li>
<li dir="ltr" aria-level="1">
Colorectal cancer remains one of the most commonly diagnosed cancers worldwide. The increasing incidence, especially in younger adults, and the expanding elderly population&mdash;who are at greater risk&mdash;are contributing to a growing mCRC patient pool, thereby driving sustained demand for both first-line and refractory treatment options.
</li>
</ul>
<h3 dir="ltr">Metastatic Colorectal Cancer Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Many of the newer targeted therapies and immunotherapies are expensive and not universally reimbursed, particularly in low- and middle-income countries. Cost-related barriers can delay or limit access to optimal care, affecting patient outcomes and restricting market growth in resource-limited settings.
</li>
<li dir="ltr" aria-level="1">
Despite treatment advances, drug resistance&mdash;particularly to anti-EGFR and chemotherapy regimens&mdash;remains a major challenge. Tumor heterogeneity and clonal evolution in mCRC limit the long-term efficacy of therapies, creating a need for continuous treatment adaptation and highlighting the unmet need for novel resistance-overcoming strategies.
</li>
</ul>
<h3 dir="ltr">Metastatic Colorectal Cancer Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
RYBREVANT (amivantamab) + Chemotherapy
</li>
<li dir="ltr" aria-level="1">
Zanzalintinib (XL092)
</li>
<li dir="ltr" aria-level="1">
Serplulimab(HLX10) + Bevacizumab + Chemotherapy
</li>
<li dir="ltr" aria-level="1">
Temab-A (ABBV-400)
</li>
<li dir="ltr" aria-level="1">
Ompenaclid (RGX-202) + Chemotherapy + Bevacizumab
</li>
<li dir="ltr" aria-level="1">
PolyPEPI1018 + Atezolizumab
</li>
<li dir="ltr" aria-level="1">
Onvansertib (PCM-075)
</li>
<li dir="ltr" aria-level="1">
Botensilimab &plusmn; Balstilimab
</li>
<li dir="ltr" aria-level="1">
Sirexatamab (DKN-01)
</li>
<li dir="ltr" aria-level="1">
Etrumadenant (AB928)
</li>
<li dir="ltr" aria-level="1">
EO4010
</li>
<li dir="ltr" aria-level="1">
TTX-080
</li>
<li dir="ltr" aria-level="1">
GCC19CART
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight">Metastatic Colorectal Cancer Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Johnson &amp; Johnson Innovative Medicine
</li>
<li dir="ltr" aria-level="1">
Shanghai Henlius Biotech
</li>
<li dir="ltr" aria-level="1">
Inspirna
</li>
<li dir="ltr" aria-level="1">
Treos Bio
</li>
<li dir="ltr" aria-level="1">
Cardiff Oncology
</li>
<li dir="ltr" aria-level="1">
Agenus
</li>
<li dir="ltr" aria-level="1">
Leap Therapeutics
</li>
<li dir="ltr" aria-level="1">
Arcus Biosciences
</li>
<li dir="ltr" aria-level="1">
Enterome
</li>
<li dir="ltr" aria-level="1">
Tizona Therapeutics
</li>
<li dir="ltr" aria-level="1">
Innovative Cellular Therapeutics
</li>
</ul>
And others.

Metastatic Colorectal Cancer

Metastatic Colorectal Cancer Market

Metastatic Colorectal Cancer Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape